Johnson & Johnson - 63 Year Stock Price History | JNJ
Historical daily share price chart and data for Johnson & Johnson since 1962 adjusted for splits and dividends. The latest closing stock price for Johnson & Johnson as of November 14, 2025 is 195.93.
- The all-time high Johnson & Johnson stock closing price was 195.93 on November 14, 2025.
- The Johnson & Johnson 52-week high stock price is 197.18, which is 0.6% above the current share price.
- The Johnson & Johnson 52-week low stock price is 140.68, which is 28.2% below the current share price.
- The average Johnson & Johnson stock price for the last 52 weeks is 163.19.
| Johnson & Johnson Historical Annual Stock Price Data | ||||||
|---|---|---|---|---|---|---|
| Year | Average Stock Price | Year Open | Year High | Year Low | Year Close | Annual % Change |
| 2025 | 163.4949 | 140.6320 | 195.9300 | 138.7180 | 195.9300 | 38.74% |
| 2024 | 149.4356 | 151.4130 | 162.1420 | 137.7620 | 141.2180 | -4.81% |
| 2023 | 149.3558 | 163.6910 | 165.5840 | 136.7170 | 148.3560 | -8.58% |
| 2022 | 156.4016 | 153.5480 | 167.5690 | 142.4620 | 162.2770 | 5.97% |
| 2021 | 146.2392 | 136.6420 | 158.6580 | 134.4810 | 153.1280 | 11.44% |
| 2020 | 125.5598 | 124.0750 | 137.4100 | 95.0719 | 137.4100 | 10.82% |
| 2019 | 113.0320 | 105.6110 | 124.4750 | 103.9330 | 123.9900 | 16.22% |
| 2018 | 108.4633 | 112.0620 | 122.2190 | 97.4341 | 106.6860 | -5.13% |
| 2017 | 103.1212 | 90.8749 | 115.0080 | 87.6742 | 112.4560 | 24.42% |
| 2016 | 87.9246 | 76.6586 | 97.0520 | 73.0500 | 90.3807 | 15.33% |
| 2015 | 74.9690 | 77.4455 | 80.2977 | 68.7136 | 78.3675 | 1.14% |
| 2014 | 73.7113 | 65.6303 | 80.4094 | 62.4508 | 77.4826 | 17.34% |
| 2013 | 60.9439 | 49.5684 | 68.9468 | 49.4984 | 66.0340 | 34.62% |
| 2012 | 45.9855 | 44.4530 | 50.2991 | 42.4641 | 49.0506 | 10.85% |
| 2011 | 42.0932 | 40.8998 | 45.0071 | 37.8798 | 44.2505 | 9.89% |
| 2010 | 39.7288 | 40.6758 | 41.8425 | 36.4630 | 40.2682 | -0.59% |
| 2009 | 35.7655 | 36.9026 | 40.8519 | 28.5890 | 40.5060 | 11.27% |
| 2008 | 38.8975 | 38.9807 | 43.5802 | 33.6656 | 36.4036 | -7.72% |
| 2007 | 37.3439 | 38.2919 | 40.4533 | 34.8026 | 39.4479 | 3.61% |
| 2006 | 35.4578 | 34.7242 | 39.6252 | 32.0028 | 38.0728 | 12.43% |
| 2005 | 36.0782 | 34.7525 | 38.5097 | 33.8283 | 33.8621 | -3.36% |
| 2004 | 30.5934 | 27.9931 | 35.2277 | 26.9410 | 35.0398 | 25.17% |
| 2003 | 28.2369 | 29.4486 | 31.3549 | 26.2796 | 27.9931 | -2.08% |
| 2002 | 30.4615 | 30.8215 | 34.4936 | 22.1173 | 28.5864 | -7.88% |
| 2001 | 27.0997 | 26.4267 | 32.0134 | 21.6413 | 31.0315 | 14.00% |
| 2000 | 22.9758 | 23.5541 | 27.2202 | 17.5650 | 27.2202 | 14.25% |
| 1999 | 23.8965 | 20.8829 | 27.1152 | 19.4465 | 23.8256 | 12.48% |
| 1998 | 18.8335 | 16.2207 | 22.4772 | 15.9558 | 21.1828 | 28.98% |
| 1997 | 14.7659 | 12.2294 | 16.6882 | 12.2294 | 16.4232 | 34.29% |
| 1996 | 11.8516 | 10.2034 | 13.2126 | 10.1428 | 12.2294 | 18.10% |
| 1995 | 8.2693 | 6.4777 | 11.0814 | 6.3885 | 10.3548 | 59.12% |
| 1994 | 5.4325 | 5.2473 | 6.5965 | 4.2877 | 6.5074 | 25.05% |
| 1993 | 4.8110 | 5.6032 | 5.6032 | 4.1062 | 5.2038 | -8.97% |
| 1992 | 5.5365 | 6.2398 | 6.4691 | 4.8360 | 5.7164 | -10.19% |
| 1991 | 4.9442 | 3.8257 | 6.4205 | 3.5866 | 6.3649 | 62.32% |
| 1990 | 3.4011 | 3.2044 | 3.9695 | 2.7829 | 3.9213 | 23.40% |
| 1989 | 2.6753 | 2.2323 | 3.1776 | 2.2323 | 3.1776 | 39.84% |
| 1988 | 2.1597 | 2.0823 | 2.3515 | 1.8538 | 2.2723 | 13.86% |
| 1987 | 2.2958 | 1.7936 | 2.7877 | 1.7186 | 1.9957 | 14.23% |
| 1986 | 1.6951 | 1.3792 | 1.9661 | 1.2695 | 1.7471 | 24.87% |
| 1985 | 1.1831 | 0.9455 | 1.4556 | 0.9322 | 1.3991 | 45.94% |
| 1984 | 0.9090 | 1.0825 | 1.1222 | 0.7489 | 0.9587 | -11.44% |
| 1983 | 1.2084 | 1.3090 | 1.3520 | 1.0394 | 1.0825 | -17.51% |
| 1982 | 1.0794 | 0.9671 | 1.3487 | 0.8585 | 1.3123 | 33.87% |
| 1981 | 0.9013 | 0.8779 | 1.0158 | 0.7523 | 0.9803 | 11.80% |
| 1980 | 0.6974 | 0.6743 | 0.8790 | 0.5843 | 0.8768 | 25.94% |
| 1979 | 0.6333 | 0.6519 | 0.7028 | 0.5688 | 0.6962 | 7.52% |
| 1978 | 0.6737 | 0.6582 | 0.7791 | 0.5782 | 0.6475 | -3.87% |
| 1977 | 0.6173 | 0.6853 | 0.6853 | 0.5494 | 0.6736 | -1.55% |
| 1976 | 0.7573 | 0.7904 | 0.8430 | 0.6316 | 0.6842 | -13.07% |
| 1975 | 0.7801 | 0.7278 | 0.8681 | 0.6467 | 0.7871 | 11.00% |
| 1974 | 0.8642 | 0.9797 | 1.0422 | 0.6587 | 0.7091 | -28.27% |
| 1973 | 1.0421 | 1.1264 | 1.1440 | 0.9161 | 0.9885 | -13.59% |
| 1972 | 1.0337 | 0.8568 | 1.1582 | 0.8316 | 1.1440 | 32.50% |
| 1971 | 0.7460 | 0.5018 | 0.8667 | 0.5018 | 0.8634 | 72.82% |
| 1970 | 0.4508 | 0.5127 | 0.5193 | 0.3275 | 0.4996 | -4.98% |
| 1969 | 0.3734 | 0.3089 | 0.5258 | 0.2958 | 0.5258 | 69.01% |
| 1968 | 0.2584 | 0.2629 | 0.3111 | 0.2184 | 0.3111 | 16.08% |
| 1967 | 0.2237 | 0.1646 | 0.2797 | 0.1617 | 0.2680 | 60.96% |
| 1966 | 0.1691 | 0.1704 | 0.1948 | 0.1362 | 0.1665 | -0.72% |
| 1965 | 0.1351 | 0.1083 | 0.1699 | 0.1083 | 0.1677 | 54.14% |
| 1964 | 0.1023 | 0.1016 | 0.1159 | 0.0935 | 0.1088 | 9.57% |
| 1963 | 0.0875 | 0.0728 | 0.1155 | 0.0723 | 0.0993 | 39.27% |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Large Cap Pharmaceutical | $472.053B | $88.821B |
| Johnson & Johnson's biggest strength is its diversified business model. It operates through pharmaceuticals, medical devices and consumer products divisions. Its diversification helps it to withstand economic cycles more effectively. J&J has one of the largest research and development (R&D) budget among pharma companies. J&J's worldwide business is divided into three segments: Pharmaceutical, Medical Devices and Consumer. The company has several drugs covering a broad range of areas such as neuroscience, cardiovascular & metabolism, immunology, oncology, pulmonary hypertension and infectious diseases and vaccines. The Medical Devices Segment offers products in the orthopedics, surgery, interventional solutions and vision markets. The Consumer Segment segment includes a broad range of products covering the areas of baby care, beauty/skin health, oral care, wound care and womens' health care, as well as over-the-counter (OTC) pharmaceutical products. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Eli Lilly (LLY) | United States | $969.283B | 46.62 |
| AbbVie (ABBV) | United States | $410.669B | 24.59 |
| Roche Holding AG (RHHBY) | Switzerland | $286.026B | 0.00 |
| Novartis AG (NVS) | Switzerland | $277.276B | 14.70 |
| Merck (MRK) | United States | $230.630B | 10.74 |
| Novo Nordisk (NVO) | Denmark | $215.481B | 12.63 |
| Pfizer (PFE) | United States | $142.484B | 7.83 |
| Sanofi (SNY) | France | $128.030B | 12.30 |
| Bayer (BAYRY) | Germany | $32.184B | 5.65 |
| Innoviva (INVA) | United States | $1.664B | 8.33 |